Clinical outcomes and remission trajectories in obese and non-obese patients with severe asthma treated with biologics: a retrospective longitudinal cohort study from the Severe Asthma Network Italy (SANI) registry
Danilo Di Bona, Giuseppe Di Gioia, Enrico Heffler, Roberta Parente, Gaetano Serviddio, Francesco Blasi, Pierluigi Paggiaro, Giorgio Walter Canonica, Diego Bagnasco, Diego Bagnasco, Luisa Brussino, Cecilia Calabrese, Gianna Camiciottoli, Marco Caminati, Giovanna Elisiana Carpagnano, Cristiano Caruso, · 2026
Read Clinical outcomes and remission trajectories in obese and non-obese patients with severe asthma treated with biologics: a retrospective longitudinal cohort study from the Severe Asthma Network Italy (SANI) registry by Danilo Di Bona, Giuseppe Di Gioia, Enrico Heffler, Roberta Parente, Gaetano Serviddio, Francesco Blasi, Pierluigi Paggiaro, Giorgio Walter Canonica, Diego Bagnasco, Diego Bagnasco, Luisa Brussino, Cecilia Calabrese, Gianna Camiciottoli, Marco Caminati, Giovanna Elisiana Carpagnano, Cristiano Caruso, (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13186060.txt.
Description
A large Italian registry study asks whether obesity blunts the benefit of biologic drugs in severe asthma. Obesity is common in this group and tracks with worse control and more side conditions, yet past findings on drug response conflict. The team followed 2,098 adults in the Severe Asthma Network Italy registry from 2017 to 2024, of whom 405, or 19.3 percent, were obese. Outcomes covered flare-ups, symptom scores, quality of life, lung function, and remission held for at least a year.
At the start, obese patients showed poorer control, lower quality of life, and more side conditions, but fewer nasal polyps and less type-2 inflammation. During follow-up, every outcome improved about the same in obese and non-obese patients. Remission by 24 months reached 22 to 25 percent, and obesity did not change the odds. The authors conclude the drugs work as well in obese patients.
Catalog record
| CREATOR | Danilo Di Bona, Giuseppe Di Gioia, Enrico Heffler, Roberta Parente, Gaetano Serviddio, Francesco Blasi, Pierluigi Paggiaro, Giorgio Walter Canonica, Diego Bagnasco, Diego Bagnasco, Luisa Brussino, Cecilia Calabrese, Gianna Camiciottoli, Marco Caminati, Giovanna Elisiana Carpagnano, Cristiano Caruso, |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 69 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |